- Investing.com
Metrics to compare | 300142 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300142PeersSector | |
|---|---|---|---|---|
P/E Ratio | 68.9x | 37.0x | −0.4x | |
PEG Ratio | 0.60 | −0.34 | 0.00 | |
Price/Book | 2.7x | 1.7x | 2.6x | |
Price / LTM Sales | 8.2x | 5.8x | 3.0x | |
Upside (Analyst Target) | −35.6% | 54.8% | 49.7% | |
Fair Value Upside | Unlock | 16.3% | 7.3% | Unlock |
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.